Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Capital Leases: 2020-2024

Historic Capital Leases for Rocket Pharmaceuticals (RCKT) over the last 5 years, with Dec 2024 value amounting to $19.4 million.

  • Rocket Pharmaceuticals' Capital Leases fell 0.04% to $19.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.4 million, marking a year-over-year decrease of 0.04%. This contributed to the annual value of $19.4 million for FY2024, which is 0.16% up from last year.
  • Latest data reveals that Rocket Pharmaceuticals reported Capital Leases of $19.4 million as of FY2024, which was up 0.16% from $19.4 million recorded in FY2023.
  • Over the past 5 years, Rocket Pharmaceuticals' Capital Leases peaked at $19.4 million during FY2024, and registered a low of $19.0 million during FY2020.
  • For the 3-year period, Rocket Pharmaceuticals' Capital Leases averaged around $19.3 million, with its median value being $19.4 million (2023).
  • Data for Rocket Pharmaceuticals' Capital Leases shows a peak YoY increased of 0.82% (in 2021) over the last 5 years.
  • Over the past 5 years, Rocket Pharmaceuticals' Capital Leases (Yearly) stood at $19.0 million in 2020, then rose by 0.82% to $19.1 million in 2021, then rose by 0.65% to $19.3 million in 2022, then rose by 0.44% to $19.4 million in 2023, then climbed by 0.16% to $19.4 million in 2024.